Polygenic Risk Scores Improve Early Heart Disease Detection

Key Points

A new multicondition polygenic risk score (PRS) report identified inherited cardiovascular risk before symptoms appeared.
Researchers validated the PRS platform using data from nearly 300,000 participants across major U.S. biobanks.
The integrated PRS model assessed risk for eight cardiovascular and metabolic conditions.
Adding PRS to traditional clinical tools improved coronary artery disease risk classification by 17%.
High genetic-risk individuals showed significantly increased odds of coronary artery disease, atrial fibrillation, severe hypercholesterolemia, and elevated lipoprotein(a).
For More Updates in Cardiology, Register for ISCC2026 Today!

Cardiovascular Polygenic Risk Scores Show Clinical Value

Cardiovascular disease remains the leading cause of mortality worldwide, yet many patients develop serious conditions despite normal routine clinical markers. A newly validated multicondition polygenic risk score (PRS) platform may help clinicians identify hidden inherited cardiovascular risk earlier and personalize prevention strategies before symptoms emerge.

Published in the Journal of the American College of Cardiology (JACC), the study analyzed genomic and electronic health record data from 245,394 participants in the All of Us Research Program and externally validated findings in 53,306 participants from the Mass General Brigham Biobank.

How Polygenic Risk Scores Improve Cardiovascular Risk Assessment

Unlike traditional cardiovascular risk models that assess factors such as blood pressure, cholesterol, age, and smoking history, polygenic risk scores (PRS) analyze thousands of genetic variants associated with inherited disease risk. In this study, researchers developed integrated PRS models for eight conditions, including coronary artery disease (CAD), atrial fibrillation (AF), type 2 diabetes mellitus (T2DM), venous thromboembolism (VTE), thoracic aortic aneurysm (TAA), severe hypercholesterolemia, extreme hypertension, and elevated lipoprotein(a).

The strongest genetic association was seen with elevated lipoprotein(a), where individuals in the highest-risk category had a 41-fold greater likelihood of elevated levels. Increased risks were also observed for CAD, AF, T2DM, and severe hypercholesterolemia. Additionally, 71.2% of participants carried at least one PRS-defined threshold linked to a threefold or higher genetic risk for cardiovascular conditions.

Observations

PRS evaluates inherited cardiovascular risk using thousands of genetic variants.
Researchers developed PRS models for eight cardiovascular and metabolic conditions.
Elevated lipoprotein(a) showed the strongest association with genetic risk.
High PRS scores were linked to increased risk of CAD, AF, T2DM, and hypercholesterolemia.
Over 71% of participants had at least one elevated genetic cardiovascular risk marker.

Why Integrated PRS Testing Matters for Preventive Cardiology

The study showed that combining PRS with traditional clinical risk tools substantially improved patient risk classification. In patients categorized as borderline or intermediate risk using the Pooled Cohort Equations, adding genetic data improved coronary artery disease risk reclassification by 17%.

Importantly, elevated PRS remained strongly associated with future cardiovascular events during a median follow-up of 7.6 years, including among adults younger than 50 years. These findings suggest genetic screening may help clinicians identify high-risk patients earlier, enabling timely lifestyle counseling, preventive therapies, and closer monitoring.

Researchers emphasized that while predictive performance was strongest in individuals of European ancestry, broader representation in genomic datasets is still needed to improve clinical accuracy across diverse populations.

Clinical Outlook for Genetic Cardiovascular Screening

The newly validated multicondition PRS report is now available as a clinically orderable test, creating opportunities for cardiologists, preventive medicine specialists, primary care physicians, endocrinologists, and nurses to incorporate genetic risk data into patient management discussions.

Explore All Cardiology CME Conferences and Online Courses

Although additional prospective validation and outcome-based research are required before PRS-guided care becomes standard practice, the study highlights the growing role of genomic medicine in preventive cardiology and precision healthcare.